CRSP supply chain intelligence for CRISPR Therapeutics AG: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CRISPR Therapeutics AG (CRSP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VERTEX | VERTEX | 90% | Collaboration expense, net, during the three months ended March 31, 2026 and 2025 was net of $ 1.2 million and $ 0.1 million, respectively, of reimbursements from Vertex related to the Vertex Hemoglo… |
| SIRIUS | SIRIUS | 75% | The Company is solely responsible for all research, development, manufacturing and global commercialization activities and associated costs for the siRNA Licensed Products, as well as all associated … |
| ACET | Adicet Bio, Inc. | 72% | Reciprocal relationship from ACET graph: ancial institution currently in receivership, if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be u… |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · re… |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the pla… |
| GLAXF | GSK plc | 72% | Reciprocal relationship from GLAXF graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from GLAXF graph: roup no longer holds the rights. The weighted average interest rate for ca… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CRSP graph: eline. We believe it has the capacity to support, in whole or in part, the manufacture and supply of product for certa… |
| JNJ | Johnson & Johnson | 72% | eline. We believe it has the capacity to support, in whole or in part, the manufacture and supply of product for certain of our current clinical programs with the capability to scale-up to support po… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing … |
| NKTX | Nkarta, Inc. | 72% | Reciprocal relationship from NKTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from NKTX graph: Item 1A. Risk Factors. An investment in shares of our common stock involves … |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME g… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from VRTX graph: f period $ $ $ Supplemental disclosure of cash flow information: Cash paid f… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VERTEX | VERTEX | 92% | Pursuant to the 2015 Collaboration Agreement, we agreed to provide technology and options to obtain licenses relating to our CRISPR/Cas technology to Vertex in exchange for a $75.0 million upfront payment. |
| ACET | Adicet Bio, Inc. | 90% | Reciprocal relationship from ACET graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from ACET graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from ACET g… |
| VRTX | Vertex Pharmaceuticals Incorporated | 90% | Reciprocal relationship from VRTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from VRTX g… |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX g… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | eline. We believe it has the capacity to support, in whole or in part, the manufacture and supply of product for certain of our current clinical programs with the capability to scale-up to support po… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing … |
| NKTX | Nkarta, Inc. | 72% | Reciprocal relationship from NKTX graph: Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, a… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | net - Vertex 4 45,949 57,509 Collaboration expense, net - Sirius 5 1,967 — Stock-based compensation expense 16,324 20,212 Depreciation expense 4,302 4,718 Other segment items 6 ( 7,317 ) ( 12,428 ) S… |
| CVC-GROUP | CVC-GROUP | 62% | heir Intellectual Property Rights, The Outcome Of Which Would Be Uncertain And Could Have A Material Adverse Effect On The Success Of Our Business.” The patent prosecution process is expensive, time-… |
| VILNIUS-UNIVERSITY-TOOLGEN-INC | VILNIUS-UNIVERSITY-TOOLGEN-INC | 62% | heir Intellectual Property Rights, The Outcome Of Which Would Be Uncertain And Could Have A Material Adverse Effect On The Success Of Our Business.” The patent prosecution process is expensive, time-… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CRSP-DEBT-8865 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-12-31. |
| CRSP-DEBT | Debt stack $586.2M | 90% | Market cache reports total debt of $586.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CRSP-OWNER-ARK-INVESTMENT-MANAGEMENT-LLC | ARK Investment Management LLC | 90% | 13F overlay lists ARK Investment Management LLC as top holder; 501 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TWST | Twist Bioscience Corporation | 100.00 | 2 | |
| TRDA | Entrada Therapeutics, Inc. | 100.00 | 2 | |
| GSK | GSK plc | 100.00 | 2 | |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 100.00 | 2 | |
| JBIO | Jade Biosciences, Inc. | 100.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 | |
| COGT | Cogent Biosciences, Inc. | 100.00 | 2 | |
| HALO | Halozyme Therapeutics, Inc. | 100.00 | 2 | |
| TPST | Tempest Therapeutics, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| ORGO | Organogenesis Holdings Inc. | 100.00 | 2 |